Analyst Price Targets — GPCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 20, 2026 12:20 pm | — | Guggenheim | $140.00 | $88.64 | TheFly | Structure Therapeutics price target raised to $140 from $90 at Guggenheim |
| January 19, 2026 10:26 pm | — | Goldman Sachs | $102.00 | $88.64 | TheFly | Structure Therapeutics moved to Buy rating at Goldman Sachs |
| December 19, 2025 1:43 pm | Ananda Ghosh | H.C. Wainwright | $90.00 | $66.45 | TheFly | Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright |
| December 12, 2025 1:10 pm | Terence Flynn | Morgan Stanley | $125.00 | $66.24 | TheFly | Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley |
| December 11, 2025 2:12 pm | — | Jefferies | $125.00 | $69.64 | TheFly | Structure Therapeutics price target raised to $125 from $79 at Jefferies |
| December 8, 2025 9:03 pm | — | Stifel Nicolaus | $90.00 | $69.98 | TheFly | Structure Therapeutics price target raised to $90 from $50 at Stifel |
| December 2, 2025 2:21 pm | Annabel Samimy | Stifel Nicolaus | $50.00 | $33.89 | StreetInsider | Stifel Reiterates Buy Rating on Structure Therapeutics (GPCR) |
| November 28, 2025 11:35 am | Ananda Ghosh | H.C. Wainwright | $60.00 | $34.22 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR) |
| September 23, 2024 3:15 am | Terence Flynn | Morgan Stanley | $118.00 | $41.92 | StreetInsider | Morgan Stanley Starts Structure Therapeutics (GPCR) at Overweight |
| September 10, 2024 7:48 am | Yasmeen Rahimi | Piper Sandler | $93.00 | $34.72 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Structure Therapeutics (GPCR) |
Latest News for GPCR
Casdin Capital sold 380,000 shares of Structure Therapeutics in the fourth quarter for an estimated $15.52 million. Meanwhile, the quarter-end position value actually increased by $38.18 million, reflecting both trading and market price movement as shares soared in the period.
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks
Aberdeen Group plc increased its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR) by 46.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 586,869 shares of the company's stock after purchasing an additional 185,245 shares during the quarter.
Structure Therapeutics Inc. has evolved from a “dark horse” to a leading contender in the oral GLP-1 obesity drug market. GPCR's market cap surged from $1.3B to $5B in five months, reflecting heightened investor confidence after a successful Phase II readout and improved competitive positioning. The weight-loss drug market has shifted to mass-market pricing, with cash options as low as $149/month, broadening patient…
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for GPCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.